MMS, a data-focused clinical research organization (CRO) in Canton Township, announced that Ben Dudley has been appointed as the company’s new chief commercial officer (CCO).
Based in the U.K., Dudley brings more than 25 years of life sciences expertise on the CRO and sponsor side, holding previous operational and commercial leadership roles at Parexel, Covance, and AstraZeneca.
As CCO at MMS, Dudley will focus on:
- Strategic growth planning, working closely with other members of the Executive Leadership Team (ELT) to refine the vision, strategy, and goals for continued growth and expansion of MMS globally.
- Commercial leadership, understanding sponsor needs and guiding customer relationship management across global accounts; and
- Marketing strategy, overseeing campaigns that showcase the value-add of MMS service offerings, which will impact our customer successes as well as have a positive impact on patient health.
“We were deliberate in our choice of a CCO who brings scientific strength, agility, and leadership to help continue to move MMS forward, and Ben’s experience is a great fit,” says Uma Sharma, CEO of MMS. “Ben’s passion for our industry, his commercial expertise, and proven leadership give us added momentum to drive our strategic vision, foster key partnerships, and significantly enhance our market presence.”
 in Canton Township, announced that Ben Dudley has been appointed as the company’s new chief commercial officer (CCO).){kind=link}